These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 21641684)

  • 1. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
    Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
    [No Abstract]   [Full Text] [Related]  

  • 2. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
    Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
    Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
    [No Abstract]   [Full Text] [Related]  

  • 3. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
    Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
    [No Abstract]   [Full Text] [Related]  

  • 4.  Pegylated interferon, but not conventional interferon therapy induced severe skin lesions.
    Li Z; Ji F; Zheng Y; An J; Peng Z
    Ann Hepatol; 2012; 11(4):570-1. PubMed ID: 22700642
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Necrotic lesion in a patient with hepatitis C virus liver disease under treatment with pegylated interferon].
    Rosel L; Blanco JR; Metota L; Oteo JA
    Enferm Infecc Microbiol Clin; 2004 Oct; 22(8):497-8. PubMed ID: 15482692
    [No Abstract]   [Full Text] [Related]  

  • 7. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
    Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
    Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Information for patients. Treatment of acute hepatitis C].
    Otón Nieto E
    Rev Esp Enferm Dig; 2011 Oct; 103(10):549. PubMed ID: 22054273
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
    Zhdanov KV; Gusev DA; Kozlov KV; Shishkin MK; Sukachev VS; Shakhmanov DM; Zhabrov SS
    Voen Med Zh; 2015 Apr; 336(4):44-9. PubMed ID: 26454938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 12. [Type 1 diabetes developing during alpha-interferon therapy: report of two cases].
    Vinagre I; Rigla M; Torras X; Enríquez J; Corcoy R
    Endocrinol Nutr; 2010 Oct; 57(8):393-5. PubMed ID: 20462813
    [No Abstract]   [Full Text] [Related]  

  • 13. Penile paraffinoma developing during treatment with pegylated interferon alfa-2a for chronic hepatitis C virus infection.
    Bachmeyer C; Moguelet P; Gombeaud T; Sbidian E; Aractingi S
    Arch Dermatol; 2011 Oct; 147(10):1232-3. PubMed ID: 22006152
    [No Abstract]   [Full Text] [Related]  

  • 14. Secondary hyperpigmentation during interferon alfa treatment for chronic hepatitis C virus infection.
    Tsilika K; Tran A; Trucchi R; Pop S; Anty R; Cardot-Leccia N; Lacour JP; Ortonne JP; Passeron T
    JAMA Dermatol; 2013 Jun; 149(6):675-7. PubMed ID: 23553009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous reactions to interferon and ribavirin.
    Chamberlain AJ; Poon E
    Intern Med J; 2004 Aug; 34(8):519. PubMed ID: 15317557
    [No Abstract]   [Full Text] [Related]  

  • 16. Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C - authors' reply.
    Hu CC; Chien RN
    Aliment Pharmacol Ther; 2013 Feb; 37(4):492. PubMed ID: 23336679
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early interruption of triple therapy with telaprevir in chronic hepatitis C due to severe adverse effects does not necessarily lead to treatment failure].
    Virolés Torrent S; López Nuñez C; Hombrados Verde M; Figa Francesch M; Ferri Iglesias MJ; Louvriex Freire R; Acero Fernández D
    Gastroenterol Hepatol; 2015 Feb; 38(2):78-81. PubMed ID: 24948444
    [No Abstract]   [Full Text] [Related]  

  • 19. [Telaprevir-induced pityriasis rubra pilaris].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 May; 140(5):414-5. PubMed ID: 23663723
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
    Papastergiou V; Skorda L; Lisgos P; Karatapanis S
    Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.